Suppr超能文献

与极早早产儿出生后早期低血压当前序贯药物治疗相关的并发症。

Complications associated with the current sequential pharmacological management of early postnatal hypotension in extremely premature infants.

作者信息

Verma Rita P, Dasnadi Shaeequa, Zhao Yuan, Chen Hegang H

机构信息

Division of Neonatology, Department of Pediatrics, Nassau University Medical CenterEast MeadowNew York.

Section of Neonatology, Department of Pediatrics, Houston Methodist Sugarland NurseriesHoustonTexas.

出版信息

Proc (Bayl Univ Med Cent). 2019 May 3;32(3):355-360. doi: 10.1080/08998280.2019.1585732. eCollection 2019 Jul.

Abstract

Early postnatal hypotension in premature infants is treated with escalating doses of vasopressor-inotropes (VI), followed by hydrocortisone if VI therapy fails. The adverse effects of this standard clinical practice have not been well reported. In a retrospective case-control study, we compared the complications associated with VI and hydrocortisone (HCVI) treatments in extremely low-birth-weight infants (≤1000 g) with contemporaneous normotensive medication-naïve controls via standard univariate and multivariate analyses. Birth weight, gestational age, and receipt of antenatal steroids did not differ between VI ( = 74) and control ( = 124) groups, while the occurrence of gestational diabetes mellitus and risks for patent ductus arteriosus, intraventricular-periventricular hemorrhage, spontaneous intestinal perforation, ventriculomegaly, and bronchopulmonary dsyplasia were higher in VI. Infants in the HCVI group ( = 69) had lower birth weight, gestational age, and receipt of antenatal steroids and higher risks for intraventricular-periventricular hemorrhage, bronchopulmonary dysplasia, air leaks, and patent ductus arteriosus than controls. Whereas the occurrences of spontaneous intestinal perforation, ventriculomegaly, and maternal diabetes mellitus did not differ, that of maternal hypertension trended to be lower in HCVI recipients ( = 0.06). In conclusion, hypotensive extremely low-birth-weight infants treated with VI or with HCVI are susceptible to intraventricular-periventricular hemorrhage, bronchopulmonary dysplasia, and patent ductus arteriosus. Furthermore, those who receive inotropes are at risk for spontaneous intestinal perforation and ventriculomegaly. Maternal diabetes mellitus increases the occurrence of hypotension, which responds to VI. Maternal hypertension does not contribute to VI responsive and tends to decrease the occurrence of VI-refractory hypotension.

摘要

早产婴儿出生后早期低血压的治疗方法是逐步增加血管升压药 - 正性肌力药(VI)的剂量,如果VI治疗失败则使用氢化可的松。这种标准临床实践的不良反应尚未得到充分报道。在一项回顾性病例对照研究中,我们通过标准单变量和多变量分析,比较了极低出生体重儿(≤1000 g)接受VI和氢化可的松联合VI(HCVI)治疗与同期血压正常且未接受过药物治疗的对照婴儿的并发症情况。VI组(n = 74)和对照组(n = 124)之间的出生体重、胎龄和产前类固醇的使用情况没有差异,但VI组中妊娠期糖尿病的发生率以及动脉导管未闭、脑室内 - 脑室周围出血、自发性肠穿孔、脑室扩大和支气管肺发育不良的风险更高。HCVI组(n = 69)的婴儿出生体重、胎龄和产前类固醇的使用情况低于对照组,脑室内 - 脑室周围出血、支气管肺发育不良、气漏和动脉导管未闭的风险高于对照组。虽然自发性肠穿孔、脑室扩大和母亲糖尿病的发生率没有差异,但HCVI治疗组母亲高血压的发生率有降低趋势(P = 0.06)。总之,接受VI或HCVI治疗的低血压极低出生体重儿易患脑室内 - 脑室周围出血、支气管肺发育不良和动脉导管未闭。此外,接受正性肌力药治疗的婴儿有自发性肠穿孔和脑室扩大的风险。母亲糖尿病会增加低血压的发生率,且对VI有反应。母亲高血压与VI反应无关,且倾向于降低VI难治性低血压的发生率。

相似文献

本文引用的文献

1
Challenges in Treating Low Blood Pressure in Preterm Infants.治疗早产儿低血压的挑战。
Children (Basel). 2015 Jun 15;2(2):272-88. doi: 10.3390/children2020272.
8
Corticosteroids for treating hypotension in preterm infants.用于治疗早产儿低血压的皮质类固醇。
Cochrane Database Syst Rev. 2011 Dec 7;2011(12):CD003662. doi: 10.1002/14651858.CD003662.pub4.
10
Angiotensin II receptor blocker induced fetopathy: 7 cases.血管紧张素II受体阻滞剂致胎儿病:7例
Klin Padiatr. 2011 Jan;223(1):10-4. doi: 10.1055/s-0030-1269895. Epub 2011 Jan 26.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验